Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?
Dr. Sarah Mrejen (France), Associate Professor Salomon Cohen (France), and Associate Professor Dinah Zur (Israel) explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.
--------
36:41
Episode 60: Pregnancy, Retina, and Uveitis: Striking the Balance in Challenging Cases
Prof. Zohar Habot-Wilner (Tel Aviv University) chairs a rich discussion with Prof. Sofia Androudi (University of Thessaly, Greece) and Prof. Sarah Touhami (University of Sorbonne) on managing retinal and uveitic diseases during pregnancy. They explore safe diagnostic tools, therapeutic dilemmas like Ranibizumab vs. Ozurdex, and the effects of pregnancy-related hormonal shifts—highlighting the importance of multidisciplinary collaboration in high-risk cases
--------
37:48
Episode 59: Demystifying Hyperreflective Foci in AMD: From Histology to Imaging
What are hyperreflective foci, and why do they matter in AMD? Prof. Stella Vujosevic is joined by Prof. Christine Curcio (University of Alabama at Birmingham) and Prof. Srinivas Sadda (Doheny Eye Institute, UCLA) to explore their significance—from donor eye histology to OCT imaging. They discuss key biomarkers, clinical implications, and how HRF can help guide treatment decisions in age-related macular degeneration
--------
29:03
Episode 58: Understanding Central Serous Chorioretinopathy: Insights, Challenges, and Future Directions
What causes central serous chorioretinopathy (CSC), and how should it be managed? In this episode, experts Camiel Boon, Sobha Sivaprasad, and Gemmy Cheung discuss the latest insights into CSC and the pachychoroid spectrum, including new imaging findings, risk factors, and treatment options like PDT, laser, and anti-VEGF
--------
37:24
Episode 57: Advancing Uveal Melanoma Treatment: Current Strategies and Future Directions
Uveal melanoma remains a significant challenge, with genetic alterations playing a crucial role in treatment decisions. In this episode, Prof Jens Folke Kiilgaard (Denmark) and Dr Emine Kilic (Netherlands) join Prof Antonia Joussen (Germany) to explore why metastases persist despite primary tumor treatment, the limitations of checkpoint inhibitors, and the latest on Tebentafusp and Darovasertib. We also discuss the role of adjuvant and neoadjuvant therapies and emerging T-cell therapies. Join us for an insightful discussion on the future of uveal melanoma treatment
Expert Discussions from the World of Retina: Exploring the latest developments in the field with world-renowned leaders. It will feature a monthly subspecialty journal club, panel discussions and interviews with key opinion leaders.
Ireland